In the News
How much does a clinical research associate impact a company’s carbon footprint? More than you might think!
Michael Cohen discusses the need to better understand our respective carbon footprints and develop solutions to reduce the environmental impact of clinical trials.
What’s APAC’s recipe of success in clinical trials market?
Ding Ming talks about the ongoing efforts foster an environment that is more conducive to clinical trials.
Real-world evidence key to navigating new policy changes
Evidera’s Ariel Berger and Almudena Olid Gonzalez discuss the expanding role of real-world evidence in drug development.
Unleashing their potential: the evolving landscape of DHTs
Jill Sommerville, Lauren Flood and Matthew Ryan outline key considerations in deploying fit-for-purpose digital health technologies in drug development.
Cracking the talent shortfall: strategies for delivering the right talent with an FSP model
Jason Tate lays out multiple approaches to weathering clinical research workforce constraints through the use of FSPs.
Therapeutic vaccines development: at the edge of a new revolution
Our subject matter experts discuss advances in therapeutic vaccines development for the prevention of infectious diseases.
Use of AUC in AAV analysis in a GMP setting
Jie Ding and Jurgen Hannig discuss how to address shortcomings in software that does not comply with GMP standards.
Bridging therapeutic areas in the evolving metabolic space: opportunities, challenges and future perspectives
Graham Ellis, executive senior director, provides an overview of important developments happening in the diabetes/obesity/metabolic space.
Moving the needle on diversity in clinical trials: where do we go from here?
Rose Blackburne discusses the latest regulatory requirements around diversity in clinical trials, how the industry is responding and what actions will help enable further progress in clinical trial health equity.